Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine

Biochemical Pharmacology

Volumn 86, Issue 6, 2013, Pages 808-815

  Müller, Fabian ^a   König, Jörg ^a   Hoier, Eva ^a   Mandery, Kathrin ^a   Fromm, Martin F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Drug transporter; Lamivudine; MATE; OCT2; Trimethoprim

Indexed keywords

CARVEDILOL; LAMIVUDINE; MATE1 PROTEIN; MATE2 K PROTEIN; ORGANIC CATION TRANSPORTER 2; PROTEIN DERIVATIVE; TOXIN; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; DRUG UPTAKE; EMBRYO; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PRIORITY JOURNAL; TRANSCYTOSIS;

EID: 84885181188     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.07.008     Document Type: Article

References (28)

1. Reis JM, Dezani AB, Pereira TM, Avdeef A, Serra CH. Lamivudine permeability study: a comparison between PAMPA, ex vivo and in situ single-pass intestinal perfusion (SPIP) in rat jejunum. Eur J Pharm Sci 2013; 48: 781-9.
2. Pereira BG, Vianna-Soares CD, Righi A, Pinheiro MV, Flores MZ, Bezerra EM, et al. Identification of lamivudine conformers by Raman scattering measurements and quantum chemical calculations. J Pharm Biomed Anal 2007; 43: 1885-9. (Pubitemid 46464005)
3. Glaxo Smith Kline. Epivir-HBV® (lamivudine) prescribing information. Basingstoke, UK: GlaxoSmithKline; January 2011, EPH:2PIL
4. Moore KH, Yuen GJ, Raasch RH, Eron JJ, Martin D, Mydlow PK, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim- sulfamethoxazole. Clin Pharmacol Ther 1996; 59: 550-8.
5. Takubo T, Kato T, Kinami J, Hanada K, Ogata H. Effect of trimethoprim on the renal clearance of lamivudine in rats. J Pharm Pharmacol 2000; 52: 315-20. (Pubitemid 30189387)
6. Minuesa G, Volk C, Molina-Arcas M, Gorboulev V, Erkizia I, Arndt P, et al. Transport of lamivudine [(-)-β-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1,2, and 3. J Pharmacol Exp Ther 2009; 329: 252-61.
7. Jung N, Lehmann C, Rubbert A, Knispel M, Hartmann P, van Lunzen J, et al. Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos 2008; 36: 1616-23.
8. Müller F, Fromm MF. Transporter-mediated drug-drug interactions. Pharmacogenomics 2011; 12: 1017-37.
9. Koepsell H. The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med 2013; 34: 413-35.
10. Nies AT, Koepsell H, Damme K, Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol 2011; 105-67.
11. Choi MK, Song IS. Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake. Biopharm Drug Dispos 2012; 33: 170-8.
12. Choi CI, Bae JW, Keum SK, Lee YJ, Lee HI, Jang CG, et al. Effects of OCT2 c.602C > T genetic variant on the pharmacokinetics of lamivudine. Xenobiotica 2013; 43: 636-40.
13. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 2005; 102: 17923-28. (Pubitemid 41798478)
14. +/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 2006; 17: 2127-35. (Pubitemid 44141902)
15. König J, Müller F, Fromm MF. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharm Rev 2013; 65: 944-66.
16. Stocker SL, Morrissey KM, Yee SW, Castro RA, Xu L, Dahlin A, et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther 2013; 93: 186-94.
17. Ito S, Kusuhara H, Yokochi M, Toyoshima J, Inoue K, Yuasa H, et al. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther 2012; 340: 393-403.
18. Motohashi H, Inui K. Multidrug and toxin extrusion family SLC47: physiological, pharmacokinetic and toxicokinetic importance of MATE1 and MATE2-K. Mol Aspects Med 2013; 34: 661-8.
19. Müller F, König J, Glaeser H, Schmidt I, Zolk O, Fromm MF, et al. Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother 2011; 55: 3091-8.
20. König J, Zolk O, Singer K, Hoffmann C, Fromm MF. Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. Br J Pharmacol 2011; 163: 546-55.
21. Takubo T, Kato T, Kinami J, Hanada K, Ogata H. Uptake of lamivudine by rat renal brush border membrane vesicles. J Pharm Pharmacol 2002; 54: 111-7. (Pubitemid 34116230)
22. Astorga B, Ekins S, Morales M, Wright SH. Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K. J Pharmacol Exp Ther 2012; 341: 743-55.
23. Zolk O, Solbach TF, König J, Fromm MF. Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch Pharmacol 2009; 379: 337-48.
24. Cui Y, König J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999; 55: 929-37. (Pubitemid 29214613)
25. Bazzoli C, Bé nech H, Rey E, Retout S, Salmon D, Duval X, et al. Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients. Antimicrob Agents Chemother 2011; 55: 3423-31.
26. Thyssen A, Cleton A, Talluri K, Leempoels J, Janssens L, Boom S, et al. No pharmacokinetic interaction between paliperidone extended-release tablets and trimethopriminhealthy subjects. Hum Psychopharmacol 2009; 24: 532-9.
27. Kim HS, Sunwoo YE, Ryu JY, Kang HJ, Jung HE, Song IS, et al. The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. Br J Clin Pharmacol 2007; 64: 645-54. (Pubitemid 47568815)
28. de Souza J, Benet LZ, Huang Y, Storpirtis S. Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers. J Pharm Sci 2009; 98: 4413-9.